Gritstone bio(US:GRTS) Prnewswire·2024-08-05 09:45Core Points - Gritstone bio, Inc. (NASDAQ: GRTS) is facing allegations of issuing materially false and misleading statements regarding its COVID-19 vaccine development and the launch of the Phase 2b CORAL Study [1] - The class period for the allegations spans from March 9, 2023, to February 29, 2024, with a deadline for shareholders to register for the class action set for August 6, 2024 [2] Allegations Summary - The company allegedly failed to disclose its inability to launch the Phase 2b CORAL Study within the promised timeframe, which could impair its ability to secure external funding [1] - This failure is said to negatively impact Gritstone's balance sheet and cash position, leading to an overstatement of its capabilities in product development and commercialization [1] - The public statements made by Gritstone during the class period are claimed to be materially false and misleading [1] Next Steps for Shareholders - Shareholders who purchased GRTS shares during the specified timeframe are encouraged to register for the class action to receive updates and monitor the case [2] - There is no cost or obligation for shareholders to participate in the case [2]